Case report

Necrotizing fasciitis in a patient receiving tocilizumab for rheumatoid arthritis – Case report

Diana Rosa-Gonçalves*, Miguel Bernardes, Lúcia Costa

Rheumatology Department, Centro Hospitalar São João, Portugal

ARTICLE INFO

Article history:
Received 3 August 2016
Accepted 28 October 2016
Available online 29 December 2016

Keywords:
Rheumatoid arthritis
Infection
Necrotizing fasciitis
Skin
Tocilizumab
Tumor necrosis factor antagonists

ABSTRACT

We present a case of necrotizing fasciitis in a 66-year-old Caucasian woman with rheumatoid arthritis receiving tocilizumab, and provide a review of published cases. The patient exhibited no systemic symptoms and discreet cutaneous inflammatory signals at presentation. She was successfully treated with broad-spectrum empiric antibiotic therapy and surgical debridement.

© 2016 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Background

Necrotizing fasciitis (NF) is a rare severe infection affecting subcutaneous tissue and superficial fascia associated with considerable mortality (70–80%).1–3 The infections are the most feared adverse events of tocilizumab (TOC); there are few published post-marketing data.

A case report of NF is presented with a published cases review through PubMed database and several European Biologics Registers.

Case report

A 66-year-old Caucasian woman with a seropositive RA presented with sudden onset of severe and progressive forearm and elbow pain with 3 days of evolution. She denied fever and history of trauma or animal bite. Since fourteen years ago, she has been consecutively treated with methotrexate (up to 20 mg/week), etanercept (50 mg weekly) and adalimumab (40 mg fortnightly), which were discontinued owing to lack of efficacy. For three years, she has been treated with prednisolone (7.5 mg/day), leflunomide (LEF) (10 mg/day) and TOC (8 mg/kg intravenous (iv) every 4 weeks). The prior medical history was significant for bacterial osteomyelitis (foot fifth digit) under TOC monotherapy for a year. Vital signs were as follow: pulse, 86beats/min; blood pressure, 135/72 mmHg; body temperature, 36.8 °C. Had active synovitis in

Palabras clave:
Artritis reumatoide
Infección
Fascitis necrosante
Piel
Tocilizumab
Antagonistas del factor de necrosis tumoral alfa

RESUMEN

Presentamos un caso de fascitis necrosante en una mujer caucásica de 66 años de edad con artritis reumatoide en tratamiento con tocilizumab y se ha realizado una revisión de casos publicados. La paciente ha presentado falta de síntomas sistémicos y señales inflamatorias cutáneas discretas. Ha sido tratada con éxito con terapia antibiótica empírica de amplio espectro y desbridamiento quirúrgico.

© 2016 Elsevier España, S.L.U. y Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. Todos los derechos reservados.

* Corresponding author.
E-mail address: dio_goncalves@hotmail.com (D. Rosa-Gonçalves).

https://doi.org/10.1016/j.reuma.2016.10.008
1699-258X/© 2016 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.
metacarpophalangeal, interphalangeal and wrist joints. Left upper limb presented diffusely oedematous with a slight erythematous rash and increased temperature. Laboratory tests were as follows: hemoglobin 12.3 g/dl; white blood cell (WBC) count 11.8 × 10⁹/l (neutrophils 10.6 × 10⁹/l); platelets 149 × 10⁹/l; C-reactive protein (CRP) 74.6 mg/l; creatinine 1.51 mg/dl; sodium 138 mEq/l and glucose 91 mg/dl. Arteriovenous Doppler ultrasound excluded venous thrombosis.

Table 1
Characterization of reported cases of necrotizing fasciitis with tocilizumab and TNFα blockers.

<table>
<thead>
<tr>
<th>Case (reference)</th>
<th>Biological agents</th>
<th>TNFs blockers/TCZ</th>
<th>Therapy duration (months)</th>
<th>CCTs</th>
<th>DM</th>
<th>Current cDMARD</th>
<th>Previous DMARD</th>
<th>Area</th>
<th>Fever at presentation</th>
<th>WBC (×10⁹/l)</th>
<th>Neutrophils (×10⁹/l)</th>
<th>CRP (mg/dl)</th>
<th>Isolated agents in skin swabs/blood cultures</th>
<th>Treatment</th>
<th>Surgical debridement/skin graft</th>
<th>Sepsis/death</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>TCZ</td>
<td>F</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>MTX, HCQ, etanercept</td>
<td>None</td>
<td>Pectoral region</td>
<td>Normal</td>
<td>3.3</td>
<td>1.8</td>
<td>3</td>
<td>Gentamicin, penicillin, clindamycin, (+IVIGs + hydrocortisone)</td>
<td>Yes/no</td>
<td>Yes/yes</td>
<td>Yes/yes</td>
</tr>
<tr>
<td>2</td>
<td>TCZ</td>
<td>F</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>MTX, HCQ, etanercept</td>
<td>None</td>
<td>Hand, Forearm</td>
<td>Normal</td>
<td>5.3</td>
<td>3.2</td>
<td>0.4</td>
<td>Not done/not done, Group A Streptococcus</td>
<td>Yes</td>
<td>Yes/yes</td>
<td>Yes/yes</td>
</tr>
<tr>
<td>3</td>
<td>TCZ</td>
<td>F</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>MTX, HCQ, etanercept</td>
<td>None</td>
<td>Leg</td>
<td>Normal</td>
<td>22.10</td>
<td>12.6</td>
<td>0.04</td>
<td>Not done/not done, Group A Streptococcus</td>
<td>Yes/yes</td>
<td>Yes/yes</td>
<td>Yes/yes</td>
</tr>
<tr>
<td>4</td>
<td>Etanercept</td>
<td>M</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>None</td>
<td>none</td>
<td>Shoulder</td>
<td>Normal</td>
<td>2,200</td>
<td>19,669</td>
<td>25.3</td>
<td>Normal</td>
<td>No</td>
<td>No</td>
<td>Yes/yes</td>
</tr>
<tr>
<td>5</td>
<td>Infliximab</td>
<td>M</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>None</td>
<td>none</td>
<td>Thigh</td>
<td>Normal</td>
<td>14,820</td>
<td>13,990</td>
<td>?</td>
<td>Group A Streptococcus</td>
<td>No</td>
<td>No</td>
<td>Yes/yes</td>
</tr>
<tr>
<td>6</td>
<td>Etanercept</td>
<td>F</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>None</td>
<td>none</td>
<td>Lower limb</td>
<td>Normal</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>Group A Streptococcus</td>
<td>No</td>
<td>No</td>
<td>Yes/yes</td>
</tr>
</tbody>
</table>

AZA, azathioprine; cDMARD, classic disease-modifying antirheumatic drugs; CCT, corticotherapy; CRP, C-reactive protein; CT, computerized tomography; DIC, disseminated intravascular coagulation; DM, diabetes mellitus; F, female; HCQ, hydroxychloroquine; IVIG, intravenous immunoglobulin; LEFL, leflunomide; MRI, magnetic resonance imaging; M, male; MTX, methotrexate; RA, rheumatoid arthritis; SSZ, sulfasalazine; TCZ, tocilizumab; WBC, white blood cell; ?, unknown.
Three days later, erythrocyte sedimentation rate was 58 mm and CRP 188.3 mg/L. Differential diagnosis included cellulitis and septic arthritis. Immunosuppressants drugs were discontinued, cholestyramine and empiric antibiotic therapy (vancomycin and imipenem) were initiated. Magnetic resonance showed peri-aponeurosis and muscle edema (especially deltoid muscle), signs of cellulitis, without organized collections. At day 5 of treatment, lesions rapidly progressed to extensive areas of skin detachment and necrosis with severe exudation (Fig. 1). She had now periodic fever. *Enterobacter aerogenes*, *Pseudomonas aeruginosa* and *Stenotrophomonas maltophilia* were identified in the skin; blood cultures were negative. Surgical debridement with subsequent partial skin graft and a twenty-days period of antibiotic led to progressive improvement. She was discharged at day 39.

After one-year follow-up there was no recurrence of infections. She is under hydroxychloroquine (400 mg/day) and prednisolone (7.5 mg/day). Methotrexate was added but soon discontinued due to oral mucositis. TOC was permanently withdrawn.

**Literature review and discussion**

We identified three case reports of NF in RA patients receiving TOC and three under TNF antagonists (Table 1). Published rates of serious skin and soft tissue infections in RA patients vary widely between different European Biologics Registers, from 12–18 per 1000 patient-years in the British register to 37–76 per 1000 patient-years in German register. Results from British register showed that the majority were cellulitis (227/309; 73%) and only four cases were NF (all with anti-TNF).

A German cohort study concluded that longer disease duration, history of severe infections, previous exposure to multiple DMARDs and concomitant treatments with LEF, prednisone or proton-pump inhibitor increase the risk of infections under TOC. This is our patient profile. In the TOWARD study, infections were more prevalent among patients receiving TOC and DMARDs simultaneously; however, there was no explicitly assigned association to LEF. Thus, we cannot overlooked that our patient was under LEF and glucocorticoids and we attribute the adverse event to their association with TOC rather than to TOC alone. TOC contribution remains speculative and causality cannot be asserted nor ruled out with certainty. So, we believe that is important to report such infections in the post-marketing surveillance.

In conclusion, physician should keep in mind that infections may mimic a disease flare and the absence of fever does not exclude serious infections in RA patients under biologics.

**Ethical disclosures**

**Protection of human and animals subjects.** The authors state that no human or animal experiments have been performed for this investigation.

**Confidentiality of data.** The authors state that they have followed the protocols of their work center on the publication of patient data.

**Right to privacy and informed consent.** The authors declare that they have received written consent from the patients and/or subjects mentioned in the article. The author for correspondence must be in possession of this document.

**Conflict of interest**

All authors declare no conflicts of interest.

**References**